VaxInnate Corp. has granted Indian biopharmaceutical company Biological E. Ltd. a license to its recombinant H1N1 flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.
VaxInnate Corp. has granted Indian biopharmaceutical company Biological E. Ltd. a license to its recombinant H1N1 flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.
This commentary was written by Bob Graham and Jim Talent ?and published in The Washington Post on Jan. 4.
WASHINGTON — The H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health.
A German research team has discovered that a severe pandemic scenario could quickly lead to a deficit of up to 96,000 red blood cell (RBC) transfusion units in Germany alone, creating potentially fatal outcomes.
WASHINGTON — Congress, the Obama administration and taxpayers need to accept that drugmakers are not going to pursue discovery and development of emergency medical countermeasures out of the kindness of their hearts.
Public health officials walking a tightrope between massive demand for vaccines and intense public scrutiny of side effects now have a new standard for evaluating the safety of their vaccination programs.
NEW YORK — School district leaders planning for H1N1 pandemics should update emergency plans using a four-step process, according to the McGraw-Hill Education Urban Advisory Resource.
WASHINGTON, D.C. — The current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether through natural disease transmission or manmade bioterrorist attacks.
Do 1 Thing readies for its annual emergency preparedness campaign designed to help Michigan residents better prepare for emergencies and disasters.
A new emergency preparedness toolkit from www.Do1thing.us is designed to help its partners better prepare employees, members and individuals for emergencies and disasters.
GAITHERSBURG, Md. — Emergent BioSolutions Inc. applauded Congress and President George W. Bush on Dec. 20, 2006, as he signed into law the Pandemic and All-Hazards Preparedness Act.